Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
Nicolas Batty,1 Ellen Kossoff,2 Grace K Dy11Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA; 2Department of Pharmacy, Roswell Park Cancer Center, Buffalo, NY, USAAbstract: Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge&am...
Saved in:
Main Authors: | Batty N (Author), Kossoff E (Author), Dy GK (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma
by: Raymond Zhao, BS, et al.
Published: (2022) -
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
by: Glen J. Weiss, et al.
Published: (2011) -
[Translated article] Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors
by: J. Kurnia Wijaya, et al.
Published: (2022) -
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
by: Pedro Carvalho Martins, et al.
Published: (2019) -
Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
by: Jayson Miedema, MD, et al.
Published: (2018)